An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors

Biomaterials

Volumn 93, Issue , 2016, Pages 1-9

  Zhao, Peng ^a   Xia, Guiquan ^b   Dong, Shuyun ^a   Jiang, Zhaong Xing ^b   Chen, Mingnan ^a  

^a UNIVERSITY OF UTAH   (United States)

^b WUHAN UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer stem cell; Immune tolerant elastin like polypeptides (iTEP) nanoparticle; Metastasis; Salinomycin

Indexed keywords

DISEASES; ELASTIN; GLYCOPROTEINS; MAMMALS; NANOPARTICLES; POLYPEPTIDES; STEM CELLS; TUMORS;

BREAST CANCER; CANCER STEM CELLS; ELASTIN-LIKE POLYPEPTIDES; METASTASIS; SALINOMYCIN;

PATHOLOGY;

ELASTIN; IMMUNE TOLERANT ELASTIN LIKE POLYPEPTIDE NANOPARTICLE; NANOCARRIER; PACLITAXEL; SALINOMYCIN; UNCLASSIFIED DRUG; 4-DIMETHYLAMINOMETHYLBENZALDEHYDE; ANTINEOPLASTIC AGENT; BENZALDEHYDE DERIVATIVE; NANOPARTICLE; PEPTIDE; PYRAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG RELEASE; ELIMINATION HALF-LIFE; FEMALE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; METASTASIS FREE SURVIVAL; METASTASIS INHIBITION; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; ORTHOTOPIC BREAST TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METASTASIS; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZALDEHYDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ELASTIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNE TOLERANCE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASM METASTASIS; PACLITAXEL; PEPTIDES; PYRANS; TISSUE DISTRIBUTION;

EID: 84962407192     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.032     Document Type: Article

References (39)

1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6(6):449-458.
2. Zhao P., et al. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol. Pharm. 2014, 11(8):2703-2712.
3. Scully O.J., et al. Breast cancer metastasis. Cancer Genomics - Proteom. 2012, 9(5):311-320.
4. Li F., et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007, 17(1):3-14.
5. Al-Hajj M., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(7):3983-3988.
6. Liu H., et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(42):18115-18120.
7. Luo M., Brooks M., Wicha M.S. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr. Pharm. Des. 2015, 21(10):1301-1310.
8. Li X., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100(9):672-679.
9. Diehn M., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458(7239):780-783.
10. Bao S., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
11. Gupta P.B., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138(4):645-659.
12. Naujokat C., Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 2012:950658.
13. Kopp F., et al. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol. Cancer 2014, 13:16.
14. Boehmerle W., Endres M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis. 2011, 2:e168.
15. Story P., Doube A. A case of human poisoning by salinomycin, an agricultural antibiotic. N. Z. Med. J. 2004, 117(1190):U799.
16. Ojo O.O., Bhadauria S., Rath S.K. Dose-dependent adverse effects of salinomycin on male reproductive organs and fertility in mice. PLoS One 2013, 8(7):e69086.
17. Wei X., et al. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013, 24(4):658-668.
18. Zhang Y., et al. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012, 33(2):679-691.
19. Yao H.J., et al. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials 2014, 35(33):9208-9223.
20. Cho S., et al. Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers. J. Drug Target. 2016 April, 24(4):328-339. PMID: 26307138.
21. Roche Lab FAQs: Find a Quick Solution 2013, fourth ed.
22. Tao K., et al. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008, 8(1):228.
23. Sheng X., et al. Isolation and enrichment of PC-3 prostate cancer stem-like cells using MACS and serum-free medium. Oncol. Lett. 2013, 5(3):787-792.
24. Manuel Iglesias J., et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One 2013, 8(10):e77281.
25. Zhou Y., Yang J., Kopecek J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 2012, 33(6):1863-1872.
26. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46(12 Part 1):6387-6392.
27. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63(3):136-151.
28. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9(8):615-627.
29. Bastianello S.S., et al. A chronic cardiomyopathy in feedlot cattle attributed to toxic levels of salinomycin in the feed. J. S. Afr. Vet. Assoc. 1996, 67(1):38-41.
30. Zhang Z., Mei L., Feng S.S. Paclitaxel drug delivery systems. Expert Opin. Drug Deliv. 2013, 10(3):325-340.
31. Peer D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nano 2007, 2(12):751-760.
32. Kontos S., Hubbell J.A. Drug development: longer-lived proteins. Chem. Soc. Rev. 2012, 41(7):2686-2695.
33. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol. 2007, 28(11):482-490.
34. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. mAbs 2009, 1(1):12-25.
35. Pulaski B.A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 2001, 39. 20.2, 20.2.1-20.2.16.
36. Mastria E.M., et al. Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. J. Control Release 2015, 208:52-58.
37. Zhou M., et al. Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model. Nanoscale 2015, 7:19438-19447.
38. Gao Z.G., et al. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles. J. Control Release 2011, 152(1):84-89.
39. Bhattacharyya J., et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat. Commun. 2015, 6:7939.